DATE: NOVEMBER 22, 2005

TO: Robert L Kladiva
US Department of Energy
Chicago Office
9800 South Cass Avenue
Argonne, IL 60439

FROM: Thomas P. Quinn
University of Missouri

SUBJECT: Final Report DE-FG02 93ER61661

Please find enclosed a paper copy and an electronic copy (CD) of the final report for DE-FG02 93ER61661. Please contact me if additional information is required. The financial documents were sent under a separate cover .

Sincerely

Thomas P. Quinn, Ph.D.
Professor of Biochemistry

TEL: 573-882-6099
FAX: 573-884-4812

ANNOUNCEMENT

PART I: STI PRODUCT DESCRIPTION (To be completed by Recipient/Contractor)

A. STI Product Identifiers

1. REPORT/PRODUCT NUMBER(s)

None

2. DOE AWARD/CONTRACT NUMBER(s)

DE FG02 93ER61661

3. OTHER IDENTIFYING NUMBER(s)

B. Recipient/Contractor

The University of Missouri, Columbia, MO

C. STI Product Title

Melanoma Therapy with Rhenium Cyclized Alpha
Melanocyte Stimulating Hormone Peptide Analogs

D. Author(s)

Thomas P. Quinn

E-mail Address(es):

quinn1@missouri.edu

E. STI Product Issue Date/Date of Publication

11/21/2005

(mm/dd/yyyy)

F. STI Product Type (Select only one)

☒ 1. TECHNICAL REPORT

☒ Final ☐ Other (specify)

☐ 2. CONFERENCE PAPER/PROCEEDINGS

Conference Information (title, location, dates)

☐ 3. JOURNAL ARTICLE

a. TYPE: ☐ Announcement Citation Only

☐ Preprint ☐ Postprint

b. JOURNAL NAME

c. VOLUME d. ISSUE

e. SERIAL IDENTIFIER (e.g. ISSN or CODEN)

☐ OTHER, SPECIFY

G. STI Product Reporting Period (mm/dd/yyyy)

3/01/2000

Thru

08/31/2005

H. Sponsoring DOE Program Office

Office of Science

Medical Applications

I. Subject Categories (list primary one first)

Keywords:

Melanoma Peptide Radiolabeling Radiotherapy

J. Description/Abstract

See Attached Report

K. Intellectual Property/Distribution Limitations

(must select at least one; if uncertain contact your
Contracting Officer (CO))

☒ 1. UNLIMITED ANNOUNCEMENT (available to
U.S. and non-U.S. public; the Government
assumes no liability for disclosure of such data)

☐ 2. COPYRIGHTED MATERIAL: Are there any
restrictions based on copyright? ☐ Yes ☒ No
If yes, list the restrictions as retained in your contract

☐ 3. PATENTABLE MATERIAL: THERE IS
PATENTABLE MATERIAL IN THE DOCUMENT
INVENTION DISCLOSURE SUBMITTED TO DOE:

DOE Docket Number: S-

(Sections are marked as restricted distribution
pursuant to 35 USC 205)

☐ 4. PROTECTED DATA: ☐ CRADA ☐ Other
If other, specify

Release date (mm/dd/yyyy)

☐ 5. SMALL BUSINESS INNOVATION RESEARCH
(SBIR) DATA

Release date (Required,

No more than 4 years from date listed in part I.E above)

☐ 6. SMALL BUSINESS TRANSFER (STTR) DATA

Release date (Required,

No more than 4 years from date listed in part I.E above)

☐ 7. OFFICE OF NUCLEAR ENERGY APPLIED
TECHNOLOGY

L. Recipient/Contractor Point of Contact Contact

For additional information (contact or organization name to be
included in published citations and who would receive any
external questions about the content of the STI Product or the
research contained therein)

Thomas P. Quinn Professor

Name and/or Position

quinn1@missouri.edu

573-88-6000

E-mail

Phone

The University of Missouri

Organization

ANNOUNCEMENT

PART II: STI PRODUCT MEDIA/FORMAT and LOCATION/TRANSMISSION

(To be completed by Recipient/Contractor)

A. Media/Format Information:

1. MEDIUM OF STI PRODUCT IS:

- ☐ Electronic Document ☐ Computer medium
☐ Audiovisual material ☒ Paper ☐ No full-text

2. SIZE OF STI PRODUCT 12 Pages

3. SPECIFY FILE FORMAT OF ELECTRONIC DOCUMENT BEING TRANSMITTED, INDICATE:

- ☐ SGML ☐ HTML ☐ XML ☐ PDF Normal ☐ PDF Image
☐ WP-Indicate Version (5.0 or greater) _____

Platform/operating system _____

- ☒ MS-Indicate Version (5.0 or greater) MS Word
2004 for
Mac

Platform/operating system _____

- ☐ Postscript _____

4. IF COMPUTER MEDIUM OR AUDIOVISUAL

- a. Quantity/type (specify) _____
b. Machine compatibility (specify) _____
c. Other information about product format a user
needs to know: _____

B. Transmission Information:

STI PRODUCT IS BEING TRANSMITTED:

- ☐ 1. Electronic via Elink
☒ 2. Via mail or shipment to address indicated
in award document (Paper products,
CD-ROM, diskettes, videocassettes, et.)

- ☐ 2a. Information product file name
(of transmitted electronic format) _____

PART III: STI PRODUCT REVIEW/RELEASE INFORMATION

(To be completed by DOE)

A. STI Product Reporting Requirement Review:

- ☒ 1. THIS DELIVERABLE COMPLETES ALL
REQUIRED DELIVERABLES FOR THIS AWARD
☐ 2. THIS DELIVERABLE FULFILLS A
TECHNICAL REPORTING REQUIREMENT,
BUT SHOULD NOT BE DISSEMINATED
BEYOND DOE.

B. DOE Releasing Official

- ☐ 1. I VERIFY THAT ALL NECESSARY

REVIEWS HAVE BEEN COMPLETED AS

DESCRIBED IN DOE G 241.1-1A, PART II,
SECTION 3.0 AND THAT THE STI
PRODUCT SHOULD BE RELEASED IN
ACCORDANCE WITH THE INTELLECTUAL
PROPERTY/DISTRIBUTION LIMITATION
ABOVE.

Released by (name) _____

Date _____
(mm/dd/yyyy)

E-mail _____

Phone _____

INSTRUCTIONS

Purpose: DOE F 241.3 provides the Office of Scientific and Technical Information (OSTI) information required to appropriately identify, process, and/or announce and disseminate the results of work funded by the U.S. Department of Energy (DOE). For general information or assistance with this form, contact OSTI at (865) 241-6435, or at the following e-mail address: 241user@adonis.osti.gov.

When to use: Submit this form with each scientific and technical information (STI) Product. Electronic format is the preferred method for submitting the announcement record and STI Product. When submitting electronically, use the electronic version of the form (<http://www.osti.gov/etlink>; discuss with your DOE Contracting Officer).

Describing the data fields: Descriptions of the various DOE F 241.3 data fields, STI Products, format, etc., can be found in ATTACHMENT 3 and other sections of the DOE G 241.1-1A, Guide to the Management of Scientific and Technical Information. Available online at <http://www.osti.gov/stip/>

DOE Financial Assistance Recipients/Contractors: Recipients and Contractors should complete Parts I and II of the form and forward the form along with the STI product to the DOE Contracting Officer who will complete the rest of the form and submit the package to OSTI.

NOTE: Sensitive, proprietary, or other STI Products for which access is restricted by statute or regulation shall not be transmitted via open systems networks (e.g., the Internet) unless authorization and/or encryption has been coordinated with OSTI in advance. This form, unless it in itself is classified, can be transmitted via open systems networks (e.g., the Internet).

RECORD STATUS - This is a required field. The record status identifies the announcement record or the STI Product as new, or revised. If the record status is not provided, the record is considered "New."

Part I: STI PRODUCT DESCRIPTION (To be completed by Recipient/Contractor)

A. STI PRODUCT IDENTIFIERS.

1. **Report/Product Number(s).** This is a required field. The unique primary report or product number assigned to the STI product. If a report number is not provided, the word "NONE" should be entered.

Following are examples of report number formats for multiple volumes, parts, or revisions:

DOEID/13734-2

DOENE/01834-1-Pt. 1

More than one report number may be provided. Multiple numbers are separated with a semicolon and a space. When more than one number is entered, the first number, considered the primary number, should identify the submitting organization. All other numbers are considered secondary numbers.

2. **DOE Award/Contract Number(s).** This is a required field. Enter the DOE award/contract number under which the work was funded. Additional DOE award/contract numbers related to the product may be entered. Multiple numbers are separated with a semicolon and a space. When more than one number is entered, the first number is considered the primary number.

3. **Other Identifying Number(s).** An additional unique identifying number assigned to the STI product. (e.g., CRADA numbers, Non-DOE contract numbers). More than one other identifying number may be provided. Multiple numbers are separated with a semicolon and a space.

B. **RECIPIENT/CONTRACTOR** - This is a required field. Provide the name and location of the organization that performed the research or issued the STI product. More than one organization may be provided; separate multiples with a semicolon and a space.

Example: University of Tennessee, Knoxville, TN

C. **STI PRODUCT TITLE** - This is a required field. Provide the title exactly as given on the product itself, including part, volume, edition, and similar information.

D. **AUTHOR(s)** - This is a required field. Provide the name of the author (last name first) of the STI product. More than one author may be provided; separate multiple entries with a semicolon and a space. If an author does not exist, the word "None" should be entered.

Examples: Jones, T.M.; Markay, Arthur R. III
Fields, J.M., ed.

Author(s) E-mail Address(es). Provide the e-mail address for each author. Multiples may be provided; they should be listed in the same order as the authors and should be separated by a semicolon and a space.

E. **STI PRODUCT ISSUE DATE/DATE OF PUBLICATION** - This is a required field. Provide the date when the information product was published or issued.

F. **STI PRODUCT TYPE** - This is a required field. It should agree with the reporting requirement identifier in the reporting requirements checklist; federal assistance reporting checklist; or in the statement of work if the product is a required deliverable that warrants accountability.

1. **Technical Report.** Identify the type of technical report provided.
2. **Conference Paper.** Provide all available conference information. An agenda alone is not sufficient for announcement.
3. **Journal Article.** Provide all available Journal Article information.

G. **STI PRODUCT REPORTING PERIOD.** Specify the beginning and ending dates of the period covered by the STI product.

H. **SPONSORING DOE PROGRAM OFFICE** - Enter the name or acronym of the DOE Program Office (e.g., Office of Science or SC) providing the funding for the work described in the STI product. For projects funded by more than one Program Office, indicate all sources of the DOE funding in descending order of dollar amount of funding appropriated. Separate multiple program offices with a semicolon and a space. If no sponsoring DOE Program Office is provided, "DOE" will be the sponsor.

I. **SUBJECT CATEGORIES** - Select one or more categories from the list provided. List the primary one first. A list of subject categories is available at (<http://www.osti.gov/etlink/>).

Keywords. Provide terms which describe the content of the publication. More than one term may be entered; separate multiple terms with a semicolon and a space.

J. **DESCRIPTION/ABSTRACT** - Provide a clear, concise, and publicly releasable English language summary of the information content of the STI product. The abstract length should be no more than 5,000 characters. If you are utilizing paper media, you may provide via attachment.

K. INTELLECTUAL PROPERTY/DISTRIBUTION LIMITATIONS - This is a required field. STI products should be written for public release; therefore, STI products should not contain proprietary, classified or any information subject to export control. Recipients/Contractors are responsible for notifying their DOE contracting officer if the document contains other than unclassified data before submitting to the DOE address in the award document. Recommendations to restrict access to STI products must have a legal basis or be accompanied by written programmatic guidance. For questions concerning current laws and guidance, refer to Part II or ATTACHMENT 7 of the DOE G 241.1-1A, Guide to the Management of Scientific and Technical Information, or contact your DOE Contracting Officer.

1. **Unlimited Announcement.** The unrestricted, unlimited distribution of the product (will be made publicly available). The Government assumes no liability for disclosure of such data.
2. **Copyrighted Material.** A copyright restriction on part or all of the contents of the STI product may affect the reproduction and distribution of the product by OSTI. Any restriction must be specified.
3. **Patentable Material.** Provide all applicable patent information.
- 4-6. No special instructions.
7. Office of Nuclear Energy Applied Technology pursuant to 10 CFR 810.

L. RECIPIENT/CONTRACTOR POINT OF CONTACT. Provide the organization or individual(s) name with corresponding contact information who will be included in the published citation as the point of contact and will respond to external questions about the content of the STI product.

Part II: STI PRODUCT MEDIA/FORMAT AND LOCATION/ TRANSMISSION
(To be completed by recipient/contractor)

A. MEDIA/FORMAT INFORMATION

1. **Medium.** This is a required field. Select one of the medium options provided. Note: When announcement record only is submitted, select "No full-text."
2. **Size of STI Product.** Provide the total number of pages or other designation which gives an indication of the size of the information product (e.g., 200 pages; 20 images; 3500 kilobytes; 3-3 1/2 inch diskettes).
3. **File Format.** This is a required field if the STI product is electronic full-text. Select one of the options provided.
4. **If Computer Medium or Audiovisual Material** (do not include software packages).

- a. Indicate the quantity and type of medium, e.g., 2 videocassettes, 1 magnetic tape.
- b. Indicate the machine with which the medium is compatible, i.e., with which it can be used (e.g., VHS, IBM PC compatible, hard disk, 6 Megs.)
- c. Enter any other information which would be helpful to the user of the STI product (e.g., programming language, file format, etc.)

B. LOCATION/TRANSMISSION INFORMATION

STI PRODUCT IS BEING TRANSMITTED:

1. This is a required field. Provide if the full-text STI product is being transmitted electronically. Indicate if product is being transmitted via Internet-accessible system called Elink at <https://www.osti.gov/eflink/>.
2. This is a required field. Provide an electronic copy of the STI product that is being transmitted via other computer-generated medium or other method. Indicate if product is being transmitted via mail or other shipment method (paper products, CD-ROM, diskettes, videocassettes, etc.). Provide information product filename of transmitted electronic format, if applicable.

Part III: STI PRODUCT REVIEW/RELEASE INFORMATION (To be completed by DOE)

A. STI PRODUCT REPORTING REQUIREMENT REVIEW

1. This is a required field if all other required STI products have been received for this award by OSTI and this STI product is the final deliverable required according to the technical information reporting requirement.
2. Indicated if the STI product is not suitable for dissemination beyond DOE based on report type or content, it is being submitted because it fulfills a technical information reporting requirement.

B. RELEASING OFFICIAL - This is a required field. Provide the name and additional information of the site's individual(s) responsible for the appropriate review and release of the STI product. Do not forward this form or the STI product until after it has been reviewed and released for announcement.

OMB BURDEN DISCLOSURE STATEMENT

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Information, Records and Resource Management, SO-31, FORS, U.S. Department of Energy, Washington, DC 20585 and to the Office of Management and Budget (OMB), Paperwork Reduction Project (1910-1400), Washington, D.C. 20503.

Abstract:

Malignant melanoma is the 6th most commonly diagnosed cancer with increasing incidence in the United States. It is estimated that 54,200 cases of malignant melanoma will be newly diagnosed and 7,600 cases of death will occur in the United States in the year 2003 (1). At the present time, more than 1.3% of Americans will develop malignant melanoma during their lifetime (2). The average survival for patients with metastatic melanoma is about 6-9 months (3). Moreover, metastatic melanoma deposits are resistant to conventional chemotherapy and external beam radiation therapy (3). Systematic chemotherapy is the primary therapeutic approach to treat patients with metastatic melanoma. Dacarbazine is the only single chemotherapy agent approved by FDA for metastatic melanoma treatment (5). However, the response rate to Dacarbazine is only approximately 20% (6). Therefore, there is a great need to develop novel treatment approaches for metastatic melanoma. The global goal of this research program is the rational design, characterization and validation of melanoma imaging and therapeutic radiopharmaceuticals. Significant progress has been made in the design and characterization of metal-cyclized radiolabeled alpha-melanocyte stimulating hormone peptides. Therapy studies with ^{188}Re -CCMSH demonstrated the therapeutic efficacy of the receptor-targeted treatment in murine and human melanoma bearing mice (previous progress report). Dosimetry calculations, based on biodistribution data, indicated that a significant dose was delivered to the tumor. However, ^{188}Re is a very energetic beta-particle emitter. The longer-range beta-particles theoretically would be better for larger tumors. In the treatment of melanoma, the larger primary tumor is usually surgically removed leaving metastatic disease as the focus of targeted radiotherapy. Isotopes with lower beta-energies and/or shorter particle lengths should be better suited for targeting metastases. The ^{177}Lu -DOTA-Re(Arg11)CCMSH and ^{212}Pb -DOTA-Re(Arg11)CCMSH complexes were developed and synthesized to investigate its ability to target and deliver an effective dose to small melanoma tumors and metastatic deposits. Dosimetry calculations for ^{188}Re -CCMSH and $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH were compared in the B16/F1 mouse melanoma flank tumor model to analyze the delivered dose to tumor and normal organs.

A synopsis of the major accomplishments over the funding period

- Successful synthesis and characterization of DOTA conjugated ReCCMSH analogs that exhibit high melanoma tumor uptake and retention and rapid whole body clearance. DOTA-ReCCMSH analogs were radiolabeled with a number of beta and alpha particle emitting isotopes including ^{177}Lu , ^{149}Pm and ^{212}Bi which possess therapeutic decay properties.
- The Maximum tolerable dose of ^{188}Re -CCMSH(Arg¹¹) is greater than 1000 $\mu\text{Ci}/\text{mouse}$. Studies showed no adverse physiological or histological side effects in mice receiving up to 1000 μCi of ^{188}Re -CCMSH(Arg¹¹).
- Therapy studies with ^{188}Re -CCMSH(Arg¹¹) demonstrated delayed tumor growth with increasing dose in both murine and human melanoma bearing mouse model systems. One human melanoma bearing scid mouse was "cured" in the 600 $\mu\text{Ci}/\text{mouse}$ trial. Higher dose mouse therapy trials at 1 mCi/mouse did not yield better therapy outcomes.
- Therapy studies with ^{177}Lu -DOTA-Re(Arg11)CCMSH demonstrated that with small melanoma tumors ^{177}Lu -DOTA-Re(Arg11)CCMSH treated animals showed no survival advantage over placebo treated animals. B16/F1 melanoma bearing animals were treated with up to 1 mCi of radioactivity. The lower energy beta emitter was not better than the high energy beta emitter Re-188 in small melanoma tumors.
- Therapy studies were performed with $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH in B16/F1 bearing melanoma animals. The mice were treated with 50, 100 and 200 microcuries of $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH. All the treated mice showed exhibited extended mean

survival times. Twenty percent of the 100 microcurie group and 45% of the 200 microcurie group survived the entire study and were melanoma free. Peptide targeted alpha-therapy was clearly most effective against small melanoma tumors than either of the beta-emitting radionuclides Re-188 or Lu-177. Since patients with end stage have disseminated metastases, short range high linear energy transfer alpha-particle emitting radionuclides like Bi-212 should be very effective.

Detailed Report:

Melanoma Therapy: The first task was to improve the synthetic yield of $^{188}\text{ReCCMSH}$ prior to beginning MTD and therapy studies. Initially, the yield of $^{188}\text{ReCCMSH}$ was approximately 10%. The low yields were primarily due to oxidation of the free thiols in the CCMSH peptide prior to complexation with ^{188}Re . The problem was eliminated by keeping our peptide preparations protected until they were ready to be used. Aliquots of CCMSH can be deprotected and prepared for labeling in 48 h. The deprotected peptide is stable in a lyophilized form for approximately three weeks. Using freshly deprotected and properly stored peptide, our yields of $^{188}\text{ReCCMSH}$ synthesis have jumped from 10% to 50% at the 50 mCi level. The amount of pure radioactive $^{188}\text{ReCCMSH}$ complex necessary for therapy studies is approximately 10 mCi. At the 10 mCi scale, the purified $^{188}\text{ReCCMSH}$ product showed instability. Two hours post purification, the $^{188}\text{ReCCMSH}$ preparation contained approximately 30 % perhenate. Injection of this test complex into tumor bearing C57 mice showed tumor uptake (10.45 ± 1.77 % ID/g) but also showed high activity in the stomach (18.21 ± 3.44 ID/g) indicative of the free perhenate. Based on the HPLC traces of the $^{188}\text{ReCCMSH}$ complex at various time points post synthesis, it appeared that the decomposition was likely due to reoxidation of the rhenium as opposed to radiolysis. To combat the unfavorable redox reaction, ascorbic acid was added to the complex synthesis reactions and to the purified sample immediately after purification. It was determined that the addition of 25 mg of fresh ascorbic acid to the reaction mixture and purified sample or to the purified sample alone resulted in dramatically improved complex stability. HPLC analysis of $^{188}\text{ReCCMSH}$ at 10 mCi/ml in the presence of 25 mg of ascorbic acid showed that the complex was stable 2, 4 and 24 h post purification. For example, *in vivo* the complex showed high tumor uptake (9.78 ± 2.00 % ID/g) and greatly reduced stomach activity values (1.93 ± 0.39 % ID/g).

Maximum tolerated dose studies were completed prior to initiating melanoma therapy studies in mice. Groups of 5 mice were injected with 100-600 uCi of $^{188}\text{ReCCMSH}$ per animal. A group of saline injected mice were used as control animals. Results for the 100 and 200 uCi per animals showed no adverse effects from radioactivity administration. No changes in white blood cell or platelet counts were observed in the mice receiving 100 and 200 uCi of $^{188}\text{ReCCMSH}$. Mice treated with 400 and 600 uCi of $^{188}\text{ReCCMSH}$ per animal showed similar serum profiles and behavior as the 100 and 200 uCi groups. Mice receiving either 400 or 600 uCi of $^{188}\text{ReCCMSH}$ exhibited weight gain and showed vigorous activity levels similar to control animals over the entire 7-week study. There was no effect on red and white blood cell levels in any of the mice receiving the higher doses of $^{188}\text{ReCCMSH}$. There was a slight decrease in white blood cell counts in the control mice on day two of the study but not in either group receiving $^{188}\text{ReCCMSH}$. The ranges of platelet levels from week 1 through 7 were, control-mice 773 to 465, 400 uCi-mice 753 to 503 and the 600 uCi-mice 688 to 471. The highs and lows were reached in the control and treatment groups during the same time point. The greatest depression in platelet counts came 5 weeks after injection in both control and treated animals. After the seven-week MTD study the animals were sacrificed and the major organs sent for a post mortem histopathology examination. Results of both the gross pathology report and the histology report on the major organs revealed no differences between treated and control groups. Since the MTD studies on $^{188}\text{Re-CCMSH}$ up to 600 uCi per mouse resulted in no observable side effects, therapeutic studies were initiated within the 100-600 uCi range.

Initial therapeutic studies were performed in B16 murine melanoma bearing C57 mice using the second-generation analog $^{188}\text{ReCCMSH}(\text{Arg}^{11})$ (Figure 1). Typical therapy trial groups contained groups of 10 mice including, normal mice, tumor-mice with no treatment, tumor mice receiving a single dose therapy or tumor mice receiving multi-dose therapy. Single dose therapy was performed with 200 μCi and 600 μCi injections of $^{188}\text{ReCCMSH}(\text{Arg}^{11})$. A multi-dose therapy trial was also performed with 2 x 400 μCi of $^{188}\text{ReCCMSH}(\text{Arg}^{11})$. Tumor mice were injected with 1 million B16 cells in the flank. Four days after injection of the B16 cells small palpable dark melanoma tumors appeared. All mice in the study were weighted and time zero blood samples were obtained prior to injection of $^{188}\text{ReCCMSH}(\text{Arg}^{11})$ or

the saline placebo through the tail vein. Tumor growth was retarded in the mice receiving the $^{188}\text{ReCCMSH}(\text{Arg}^{11})$ injections, with greater regression in growth seen at the higher dose.

Representative tumor sizes at day 3 pi were 0.05 cm^3 , 0.04 cm^3 and 0.02 cm^3 for the control, 200 μCi and 600 μCi groups, respectively. By day 7 the tumor sizes were 0.27 cm^3 , 0.23 cm^3 and 0.17 cm^3 for the control, 200 μCi and 600 μCi groups. A greater retardation of tumor growth was obtained with the 2 x 400 μCi multi-dose therapy trial. Animals received a 400 μCi injection on day 0 and a second dose on day 3. The tumor sizes were 0.03 cm^3 on day 3 and 0.15 cm^3 at day seven. None of the animal showed adverse side effects from the radiation doses. Red and white cell counts as well as platelet counts were similar between the control non-tumor bearing mice and the tumor mice receiving $^{188}\text{ReCCMSH}(\text{Arg}^{11})$.

While administration of $^{188}\text{ReCCMSH}(\text{Arg}^{11})$ caused measurable delays in tumor grow, none of the mice exhibited cures. B16 melanoma tumors are very aggressive and invasive. Mice injected with 1 million B16 cells subcutaneously generally survive 12-14 days. $^{188}\text{ReCCMSH}(\text{Arg}^{11})$ therapy did increase the mean life expectancy of the B16 tumor bearing mice. The mean life expectancy for the untreated control group was 13.6 ± 1.3 days with the 200 μCi , 600 μCi and 2x400 μCi treatment groups exhibiting 14.2 ± 1.0 day, 14.3 ± 1.3 day and 17.3 ± 1.9 day expectancies, respectively. A significant increase in survivability was observed for the 2x400 μCi treatment group but not in the single dose groups. The results from this initial therapy study indicated that multi-dose therapy was more effective than high activity single dose therapy. These results will be incorporated into our experimental design for the next therapy studies performed in human melanoma bearing scid mice.

Therapy trials were also performed in TBM-13 human melanoma bearing Scid mice. Typical therapy trial groups contained groups of 10 mice including, normal mice, tumor-mice with no treatment, tumor mice receiving a single dose therapy or tumor mice receiving multi-dose therapy. Single dose therapy was performed at 600 μCi per animal while a multi-dose therapy trial was performed at 2 x 400 μCi . Tumor mice were injected with 1 million B16 cells in the flank. All mice in the study were weighted and time zero blood samples were obtained prior to injection of $^{188}\text{Re-CCMSH}(\text{Arg}^{11})$ or the saline placebo through the tail vein.

Tumor growth was retarded in the mice receiving the $^{188}\text{Re-CCMSH}(\text{Arg}^{11})$ injections, with greater inhibition observed in the single dose 600 μCi group. For example the average tumor sizes for the control non treated group and the 2x400 μCi and 600 μCi treatment groups 18 days after therapy were 0.263 cm^3 , 0.160 cm^3 and 0.061 cm^3 , respectively. Delays in tumor growth translated into increased mean life expectancies. None of the animal showed adverse side effects from the $^{188}\text{Re-CCMSH}(\text{Arg}^{11})$ radiation doses. Red and white cell counts as well as platelet counts were similar between the control non-tumor bearing mice and the tumor mice (data not shown). The mean life expectancy for the non treatment control group was 39.6 ± 15.0 , with the 600 μCi and 2x400 μCi groups displaying mean life expectancies

Table 1: Biodistribution comparison among ^{111}In -labeled DOTA-ReCCMSH (ReCCMSH), DOTA-CCMSH (CCMSH), DOTA-CMSH (CMSH), and DOTA-NDP (NDP) in B16/F1 murine melanoma bearing C57 mice at 0.5, 2, 4 and 24 h p.i. (% ID/g) (n = 5) (mean $\pm$ SD).

		Tumor	Blood	Muscle	Heart	Lung	Liver	Kidney
0.5 h	ReCCMSH	10.4 $\pm$ 1.75	1.57 $\pm$ 0.37	0.42 $\pm$ 0.17	0.72 $\pm$ 0.21	1.70 $\pm$ 0.55	0.59 $\pm$ 0.15	13.0 $\pm$ 3.21
	CCMSH	7.26 $\pm$ 2.00*	9.37 $\pm$ 0.93***	0.49 $\pm$ 0.14	2.13 $\pm$ 0.29***	5.12 $\pm$ 1.65***	2.85 $\pm$ 0.33***	73.4 $\pm$ 12.1***
	CMSH	8.46 $\pm$ 1.48	1.89 $\pm$ 0.19	0.29 $\pm$ 0.11	0.54 $\pm$ 0.12	0.93 $\pm$ 0.14	0.69 $\pm$ 0.09	34.1 $\pm$ 4.4***
	NDP	8.31 $\pm$ 2.02	0.59 $\pm$ 0.06**	4.49 $\pm$ 0.47***	0.43 $\pm$ 0.20*	0.67 $\pm$ 0.20***	0.58 $\pm$ 0.06	8.96 $\pm$ 2.24*
2 h	ReCCMSH	11.4 $\pm$ 2.89	0.07 $\pm$ 0.03	0.05 $\pm$ 0.03	0.07 $\pm$ 0.05	0.18 $\pm$ 0.07	0.23 $\pm$ 0.01	8.98 $\pm$ 0.82
	CCMSH	5.89 $\pm$ 1.88**	1.20 $\pm$ 0.32**	0.11 $\pm$ 0.04*	0.43 $\pm$ 0.14**	1.07 $\pm$ 0.22***	1.20 $\pm$ 0.31**	63.2 $\pm$ 15.6***
	CMSH	7.51 $\pm$ 0.98*	0.41 $\pm$ 0.10**	0.06 $\pm$ 0.03	0.07 $\pm$ 0.07	0.29 $\pm$ 0.06*	0.46 $\pm$ 0.04**	38.4 $\pm$ 3.6**
	NDP	8.62 $\pm$ 3.30	0.22 $\pm$ 0.08**	4.46 $\pm$ 0.72***	0.19 $\pm$ 0.10	0.74 $\pm$ 0.18**	0.54 $\pm$ 0.04***	12.0 $\pm$ 1.96*
4 h	ReCCMSH	9.49 $\pm$ 0.90	0.03 $\pm$ 0.03	0.09 $\pm$ 0.06	0.12 $\pm$ 0.10	0.11 $\pm$ 0.05	0.20 $\pm$ 0.04	9.27 $\pm$ 2.65
	CCMSH	4.32 $\pm$ 0.59***	0.82 $\pm$ 0.13***	0.17 $\pm$ 0.10	0.42 $\pm$ 0.09**	0.86 $\pm$ 0.34**	1.37 $\pm$ 0.47**	67.7 $\pm$ 8.1***
	CMSH	6.72 $\pm$ 1.21**	0.16 $\pm$ 0.06**	0.17 $\pm$ 0.10	0.18 $\pm$ 0.08	0.30 $\pm$ 0.24	0.44 $\pm$ 0.04**	37.0 $\pm$ 4.9***
	NDP	7.45 $\pm$ 2.38	0.11 $\pm$ 0.03**	3.32 $\pm$ 0.51***	0.30 $\pm$ 0.26	0.35 $\pm$ 0.14*	0.56 $\pm$ 0.11***	12.9 $\pm$ 2.49
24 h	ReCCMSH	4.86 $\pm$ 1.52	0.01 $\pm$ 0.01	0.03 $\pm$ 0.01	0.12 $\pm$ 0.11	0.06 $\pm$ 0.04	0.15 $\pm$ 0.02	5.64 $\pm$ 1.31
	CCMSH	1.91 $\pm$ 0.56**	0.08 $\pm$ 0.02**	0.04 $\pm$ 0.02	0.14 $\pm$ 0.04	0.15 $\pm$ 0.05*	0.72 $\pm$ 0.03***	45.5 $\pm$ 5.1***
	CMSH	3.09 $\pm$ 0.32*	0.02 $\pm$ 0.01**	0.02 $\pm$ 0.01	0.08 $\pm$ 0.08	0.12 $\pm$ 0.10	0.28 $\pm$ 0.05**	21.8 $\pm$ 1.7***
	NDP	2.47 $\pm$ 0.79*	0.02 $\pm$ 0.02	0.73 $\pm$ 0.22**	0.11 $\pm$ 0.08	0.25 $\pm$ 0.18	0.38 $\pm$ 0.11*	10.2 $\pm$ 2.72*

* 0.05 > P > 0.01; ** 0.01 > P > 0.001; P < 0.001

To determine if Re-cyclization was necessary for high tumor uptake values and favorable pharmacokinetics of DOTA-ReCCMSH, several closely related non-Re cyclized analogs were synthesized for comparison. Compared with its linear counterpart ^{111}In -DOTA-CCMSH complex, the cyclized ^{111}In -DOTA-ReCCMSH complex exhibited a significant increase *in vivo* tumor targeting capacity. Uptake values for the Re-cyclized ^{111}In -DOTA-ReCCMSH complex and linear ^{111}In -DOTA-CCMSH complex were 9.49 $\pm$ 0.90 and 4.32 $\pm$ 0.59 % ID/g 4 h post injection. The tumor uptake value for the Re-cyclized complex (9.49 $\pm$ 0.90 % ID/g) was also significantly higher than the disulfide bond-cyclized complex (6.72 $\pm$ 1.21 % ID/g), indicating that the two methods of peptide cyclization were not equivalent. ^{111}In -DOTA-NDP tumor uptake was also lower (7.45 $\pm$ 2.38 % ID/g), without significance, than that of ^{111}In -DOTA-ReCCMSH (9.49 $\pm$ 0.90 % ID/g), although it exhibited an unexpectedly high accumulation in the muscle (3.32 $\pm$ 0.51 % ID/g). These results clearly showed that Re-cyclization was critical for high tumor uptake and retention as well as rapid clearance from normal tissues.

An comparison of the kidney uptake values for the ^{111}In -DOTA-MSH complexes at 2 h post injection showed that ^{111}In -DOTA-ReCCMSH had the lowest retention value. The kidney activity levels for ^{111}In -DOTA-ReCCMSH, ^{111}In -DOTA-CCMSH, ^{111}In -DOTA-CMSH, and ^{111}In -DOTA-NDP were 8.98 $\pm$ 0.82, 63.2 $\pm$ 15.6, 38.4 $\pm$ 3.6, and 12.0 $\pm$ 1.96 % ID/g, respectively. Re cyclization appears to be responsible for the superior whole-body clearance properties of ^{111}In -DOTA-ReCCMSH compared to the other closely related analogs. The analogs with free thiols or a disulfide bond have significantly higher kidney retention values than their Re-cyclized counterpart.

Finally, we focused on reducing the non-specific kidney activity associated with ^{188}Re -CCMSH and ^{111}In -DOTA-ReCCMSH. The dose limiting normal tissue in our therapy studies will be the kidney, since approximately 95% of the injected dose clears through this organ. The initial kidney activities of ^{188}Re -CCMSH and ^{111}In -DOTA-ReCCMSH 30 min post injection were 16.08 $\pm$ 3.58 and 13.0 $\pm$ 3.21 % ID/g, respectively. Both Re-cyclized analogs showed superior kidney clearance properties to the $^{99\text{m}}\text{Tc}$ -cyclized homolog $^{99\text{m}}\text{Tc}$ -CCMSH (20.6 $\pm$ 2.4 % ID/g) at 30 min post injection. The ability of amino acids or amino acid derivatives to further reduce non-specific kidney retention was systematically

investigated. The effects of ^{111}In -DOTA-ReCCMSH co-injection with lysine (30 mg) or ip injection of poly-lysine (1mg), cysteine (15 mg), cysteine dimethylester (10 mg), and dimercaptosuccinate (5 mg) 30 min prior to ^{111}In -DOTA-ReCCMSH injection were investigated in normal mice. Kidney uptakes for the lysine, polylysine, cysteine dimethylester and dimercaptosuccinate 2 h post injection were 4.30 ± 0.30 , 5.71 ± 0.50 , 5.51 ± 0.53 , 7.13 ± 1.18 , and 9.58 ± 1.50 % ID/g, respectively. These results showed that co-injection of lysine-HCl was capable of reducing kidney uptake by another 50% to 4.30 ± 0.30 % ID/g. Free cysteine was equally effective in reducing kidney uptake as polylysine. Cysteine dimethylester and dimercaptosuccinate injection did not show any kidney protective properties. This result was very interesting in light of the biodistribution results presented for the non Re-cyclized ^{111}In -DOTA-CCMSH molecule. It appears that free sulfhydryls contribute significantly to non-specific kidney uptake. IP injection of free cysteine prior to radiolabeled peptide injection appears to have a protective effect on the kidney. It is evident from these results that lysine co-injection will be important in reducing non-specific kidney damage during our therapy studies. A cocktail of lysine and cysteine may be even more effective in reducing kidney retention of our radiolabeled ReCCMSH analogs.

Table 2: MSH analogs used in studies to improve tumor uptake and reduce kidney retention.

ReCCMSH	Ac-Cys-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-NH ₂
DOTA-ReCCMSH	DOTA-Cys-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-NH ₂
Ac-Lys(DOTA)-ReCCMSH	Ac-(Lys-DOTA)-Cys-Cys-glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-NH ₂
DOTA-ReCCMSH(Arg ¹¹)	DOTA-Cys-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Arg-Pro-Val-NH ₂
DOTA-ReCCMSH-OH	DOTA-Cys-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-OH
DOTA-ReCCMSH-Asp14-OH	DOTA-Cys-Cys-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-Asp-OH
NDP	Ac-Ser-Tyr-Ser-Met-Glu-His-D-Phe-Arg-Trp-Cys-Lys-Pro-Val-NH ₂

ReCCMSH Analog Refinement: Chemical characterization of [D-Lys]-ReCCMSH and DOTA-ReCCMSH were performed to develop ReCCMSH analogs with greater radiolabeling versatility and improved tumor to normal organ ratios. Several DOTA-ReCCMSH analogs, Ac-Lys(DOTA)-ReCCMSH, DOTA-ReCCMSH(Arg¹¹), DOTA-ReCCMSH-OH, and DOTA-ReCCMSH-Asp14-OH were synthesized using solid phase peptide synthesis (SPPS) followed by rhenium cyclization. The biodistribution of [DOTA-D-Lys]-ReCCMSH was compared to [DOTA]-ReCCMSH to see if the location and/or chemical linkage of DOTA affected the biodistribution patterns of the molecules. The IC-50 values of the metalloptides were determined through competitive binding assays against (1-125-Tyr-2)-NDP. Radiolabeling of the DOTA-rhenium cyclized peptides with ^{111}In was carried out in NH₄OAc (0.1 M; pH 5.5) buffered solution for 30 min at 70 degrees C. The stability of radiolabeled complexes was demonstrated in 0.01 M pH 7.4 PBS/0.1% BSA. After separation of the radiolabeled peptide from the unlabeled peptide by RP-HPLC, the biodistribution of the radiolabeled complexes was performed in C57 mice bearing B16/F1 murine melanoma tumors. All radiolabeled complexes showed fast blood clearance (2 h p.i. ^{111}In -DOTA-ReCCMSH, $0.07\pm0.03\%$ ID/g, Ac-Lys(^{111}In -DOTA)-ReCCMSH $0.09\pm0.06\%$ ID/g, ^{111}In -DOTA-ReCCMSH(Arg¹¹) $0.21\pm0.08\%$ ID/g), and their clearance was predominantly through the urine (4 h p.i. $93.5\pm1.7\%$, $87.8\pm6.5\%$, and $89.8\pm4.2\%$ (%ID) for ^{111}In labeled DOTA-ReCCMSH, Ac-Lys(DOTA)-ReCCMSH, and DOTA-ReCCMSH(Arg¹¹), respectively. Tumor uptake values of 9.45 ± 0.90 , 6.01 ± 2.36 , and 17.41 ± 5.61 (%ID/g) for ^{111}In labeled DOTA-ReCCMSH, Ac-Lys(DOTA)-ReCCMSH, and DOTA-ReCCMSH(Arg¹¹), at 4 h p.i., were observed, respectively. The kidney uptake was 9.27 ± 2.65 %ID/g for ^{111}In -DOTA-ReCCMSH, 19.02 ± 2.63 %ID/g for Ac-Lys(^{111}In -DOTA)-ReCCMSH and 7.37 ± 1.13 %ID/g for ^{111}In -DOTA-ReCCMSH(Arg¹¹) at 4 h post injection. ^{111}In -DOTA-ReCCMSH(Arg¹¹) showed high melanoma uptake and lower kidney uptake than the corresponding Lys11 analogs, supporting the theory that lysine itself contributes to appreciable kidney uptake of DOTA-ReCCMSH. Neither DOTA-ReCCMSH-OH, nor DOTA-ReCCMSH-Asp-OH showed superior tumor/kidney ratios to DOTA-ReCCMSH or Ac-Lys(DOTA)-

ReCCMSH. The presence of more ionizable groups and an overall net negative charge did not improve kidney clearance over the Lys-11 to Arg substitution.

Based on the improved tumor uptake properties and lower kidney retention characteristics of the DOTA conjugated Ac-Lys-ReCCMSH(Arg¹¹) analog, the original ReCCMSH sequence was altered to contain arginine, at position 11 instead of lysine. The goal was to determine the optimal amino acid at this position. Also, biodistribution data from ReCCMSH and its analogs suggested that the kidneys are likely to be a dose-limiting organ. Therefore, lysine, arginine and a mixture of lysine and arginine were co-injected with radiolabeled ReCCMSH complexes to determine their efficacy in reducing activity in the kidneys. The pharmacokinetics of ¹⁸⁸Re-CCMSH and ¹⁸⁸Re-CCMSH(Arg¹¹) were determined in B16/F1 murine melanoma bearing C57 mice. The tumor uptake values of ¹⁸⁸Re-CCMSH and ¹⁸⁸Re-CCMSH(Arg¹¹) were 15.03±5.20% ID/g and 20.44±1.91% ID/g at 1 hr post-injection and 1.94±0.47% ID/g and 3.50±2.32% ID/g at 24 hr post injection. Renal retention of ¹⁸⁸Re-CCMSH(Arg¹¹) was 11.79±1.29 ID/g and 3.67±0.51 ID/g at 1 hr and 4 hr post injection, which was a greater than 50% reduction compared with ¹⁸⁸Re-CCMSH. The Arg for Lys substitution in ¹⁸⁸Re-CCMSH(Arg¹¹) resulted in improved tumor uptake and retention properties coupled with reduced kidney retention. Co-injection of *L*-lysine, *D*-lysine *L*-arginine, and a combination of *L*-lysine and *L*-arginine were also investigated for their abilities to improve the tumor to kidney uptake ratios reducing of the radiolabeled complexes. Renal retention of both ¹⁸⁸Re-CCMSH and ¹⁸⁸Re-CCMSH(Arg¹¹) were significantly reduced by co-injection of twenty milligrams of *L*-lysine, *L*-arginine, and a combination of *L*-lysine and *L*-arginine. Tumor to kidney ratios for ¹⁸⁸Re-CCMSH and ¹⁸⁸Re-CCMSH(Arg¹¹) were reduced by 46% and 32%, respectively. However, even with amino acid co-injection, the tumor/kidney ratio of ¹⁸⁸Re-CCMSH was lower than that of ¹⁸⁸Re-CCMSH(Arg¹¹). The improved tumor uptake and reduced kidney retention of ¹⁸⁸Re-CCMSH(Arg¹¹) will facilitate targeted irradiation of melanoma tumors while minimizing the dose to the kidneys.

Lu-177[DOTA]-ReCCMSH(Arg¹¹) biodistribution studies: Initial ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) biodistribution studies were performed with in B16/F1 murine melanoma bearing mice. [DOTA]-ReCCMSH(Arg¹¹) was labeled with ¹⁷⁷Lu (Univ. Missouri Research Reactor, MURR). For biodistribution studies, 4 µCi of HPLC purified ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) was injected into tumor bearing C57 mice through the tail vein. The mice were sacrificed at various time points and the tumor and normal tissues of interest were collected, weighed and counted. Results from the ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) biodistribution study are shown in Table 4. The biodistribution results demonstrate that the ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) complex excellent tumor uptake and retention properties (Table 4A). Clearance through the normal tissues was rapid except for the kidneys, which displayed similar or greater activity as the tumor. Activity in the tumor could be effectively quenched by co-injection of the super potent α-MSH analog NDP, indicating that tumor uptake was receptor mediated (Table 4B). NDP co-injection did not affect activity levels in the kidney suggesting that the activity was not receptor mediated.

A	% ID/gram		
Tissues	1hr	4hr	24hr
Tumor	14.48±0.85	17.68±3.32	9.05±4.31
Brain	0.06±0.06	0.13±0.12	0.10±0.03
Blood	0.19±0.22	0.12±0.16	0.12±0.07
Heart	0.01±0.02	0.12±0.10	0.17±0.11
Lung	0.69±0.28	0.02±0.03	0.05±0.05
Liver	0.44±0.05	0.43±0.07	0.49±0.07
Spleen	0.22±0.26	0.12±0.13	0.10±0.00
Stomach	0.47±0.40	0.26±0.29	0.73±0.21
Kidneys	17.99±2.47	19.09±2.38	13.75±3.72
Muscle	0.20±0.23	0.21±0.15	0.04±0.03
Pancreas	0.19±0.22	0.30±0.30	0.02±0.02
Carcass	0.18±0.05	0.15±0.05	0.11±0.01
Bone	0.07±0.09	0.25±0.19	0.21±0.05
	% ID		
Intestine	0.42±0.15	0.79±0.51	0.39±0.08
Urine	91.69±0.57	92.20±1.21	93.44±0.91

B	% ID/gram 1 hr
Tissues	¹⁷⁷ Lu-MSH+ NDP
Tumor	0.92±1.30
Brain	0.07±0.10
Blood	0.21±0.30
Heart	0.00±0.00
Lung	0.91±0.71
Liver	1.78±0.45
Spleen	1.80±0.01
Stomach	0.68±0.66
Kidneys	21.58±3.85
Muscle	0.05±0.07
Pancreas	0.46±0.64
Carcass	0.16±0.01
Bone	0.00±0.00
	% ID
Intestine	0.47±0.04
Urine	90.70±0.21

Table 4. (A) Biodistribution of ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) or (B) ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) (¹⁷⁷Lu-MSH) plus the super potent α -MSH analog NDP or L-lysine (25 mg) co-infusion in B16/F1 murine melanoma C57 mice (% ID/g and % ID, n=4).

The therapeutic efficacy of ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) was examined in the B16/F1 flank melanoma mouse model. Mice were treated with 500 microcuries and 1000 microcuries of ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) or a saline placebo. Typical therapy trial groups contained groups of 10 mice including, normal mice, tumor-mice with no treatment, tumor mice receiving a single dose therapy. Tumor mice were injected with 1 million B16 cells in the flank. Four days after injection of the B16 cells small palpable dark melanoma tumors appeared. All mice in the study were weighted and time zero blood samples were obtained prior to injection of ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹). Mice were injected with ¹⁷⁷Lu[DOTA]-ReCCMSH(Arg¹¹) through the tail vein on day 1 (Figure 7).

All of the animals tolerated the doses with no signs of adverse effects from radiation. Mean survival times for the un treated controls was 13.3±2.3 days, while mice receiving 2x500 μ Ci exhibited a mean survival of 15.1±1.8 days and the 1000 μ Ci group 16.2±3.6 days. An examination of the tumor growth data showed that there was no statistical difference in tumor growth between the treatment groups and the placebo groups. Survival analysis also demonstrated no statistically significant improvement in mean life extension. Lu-177 therapy resulted in the lowest absorbed dose to the tumor per dosimetry calculations (see section III). This may explain the lack of therapeutic efficacy at the doses administered. It appears that one would have to double the administered dose to significant improvements in survival.

Biodistribution studies of 90Y-[DOTA]-Re(Arg¹¹)CCMSH.

C57 BL/6 female mice, 7-8 weeks old, were inoculated subcutaneously in the right flank with one-million cultured B16/F1 murine melanoma cells. Ten days after the inoculation, when tumors reached a weight of approximately 500 mg, each mouse was injected with 2 μ Ci of 90Y-labeled peptide through the tail vein for in vivo studies. After radioactivity administration, the mice were housed separately and their urine and feces were collected. Groups of 5 mice were sacrificed at different time points of post injection. Tumors and normal tissues of interest were dissected, and the blood on the samples was sponged off with gauze. Contents in the gastrointestinal tract were not removed. The whole body and tissue samples were weighed and their radioactivity measured in a gamma counter. The total blood value

was counted as 6.5% of the whole body weight. The radioactivity uptake in the tumor and normal tissues of interest was expressed as a percentage of the injected radioactivity dose per gram of tissue (% ID/g) or percentage of the injected dose (% ID). All the animal studies were carried out in compliance with Federal and local Institutional rules for the conduct of animal experimentation. Statistical analysis was performed using the Students t-test for unpaired data. ^{90}Y -[DOTA]-Re(Arg11)CCMSH exhibited fast cellular internalization and long cellular retention in B16/F1 cells. The tumor uptake of ^{90}Y -[DOTA]-Re(Arg11)CCMSH was 25.70 ± 4.64 %ID/g and 14.09 ± 2.73 %ID/g at 2 and 4 hrs post-injection in B16/F1 melanoma bearing C57 mice (8). There was very little activity in blood and major organs such as liver, lung and muscle except for the kidney, which was main excretion organ for ^{90}Y -[DOTA]-Re(Arg11)CCMSH. The kidney uptake of ^{90}Y -DOTA-Re(Arg11)CCMSH was 28.03 ± 4.66 %ID/g and 24.86 ± 4.89 %ID/g at 2 and 4 hrs post-injection in B16/F1 melanoma bearing C57 mice.

III. Dosimetry Studies.

Dosimetry calculations were performed by Darrell Fisher, Pacific Northwest National Laboratories for ^{188}Re -(Arg11)CCMSH and ^{177}Lu [DOTA]-Re(Arg11)CCMSH based on biodistribution studies performed in B16/F1 melanoma bearing mice. The absorbed dose to the B16/F1 melanoma tumor from ^{188}Re -(Arg11)CCMSH was 3.022 cGy/uCi. The primary and secondary critical normal organs were large intestine and kidneys, with absorbed dose of 1.462 cGy/uCi and 0.685 cGy/uCi, respectively. The dosimetry calculations for ^{90}Y -[DOTA]-Re(Arg11)CCMSH were 3.67 cGy/uCi to the tumor and 0.73 cGy/uCi to the intestine and 4.88 cGy/uCi to the kidneys. Overall, the dose from ^{90}Y -[DOTA]-Re(Arg11)CCMSH was approximately 20% higher than ^{188}Re -(Arg11)CCMSH. However, the kidney dose was approximately 8 times the dose deposited by ^{188}Re -(Arg11)CCMSH. These results demonstrate that kidney protective measures will have to be employed if ^{90}Y -[DOTA]-Re(Arg11)CCMSH is used for therapy. The lower energy beta emitter ^{177}Lu had approximately half the deposited energy per administered microcurie of activity that ^{188}Re or ^{90}Y . The absorbed dose to the tumor was 1.48 cGy/uCi. The kidney dose was 0.428 cGy/uCi, which was in the same range as the high energy beta emitter ^{90}Y and ^{188}Re labeled peptide. There was greater non-specific retention of the ^{177}Lu radiolabeled peptide than the ^{188}Re or ^{90}Y radiolabeled peptides resulting in the high absorbed dose to the kidneys. Finally, the dosimetry calculations for alpha-particle emitting were compared to their beta emitting counterparts. Calculated energy deposition from $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH was 61.2 cGy/uCi to the tumor and 2.58 cGy/uCi to the intestine and 36.1 cGy/uCi to the kidneys. Overall, the dose from $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH was 20 times higher per uCi than ^{188}Re -(Arg11)CCMSH or ^{90}Y -[DOTA]-Re(Arg11)CCMSH. Preliminary therapy results appear to be consistent with the dosimetry findings in that tumor progression is greatly delayed or is reversed and cured in mice receiving 100 or 200 uCi $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH. The $^{212}\text{Pb}/^{212}\text{Bi}$ [DOTA]-Re(Arg11)CCMSH therapy appears to be far more potent than ^{188}Re -, ^{90}Y -, or ^{177}Lu -(Arg11)CCMSH in small but highly aggressive B16/F1 melanoma tumors.

In summary the dosimetry calculations fit the therapy results. The high LET alpha emitter yielded the highest therapy result followed by the low LET but high energy beta emitter ^{188}Re and lastly the lower energy beta emitter ^{177}Lu . We would predict the ^{90}Y therapy would yield similar results to ^{188}Re therapy, based on the dosimetry results. Our results support peptide targeted high energy beta-emitters like Re-188 and Y-90 for radiotherapy of large tumors or large tumor burdens while peptide targeted alpha-emitters would be the clear choice for smaller metastatic tumor deposits. Pb-212/Bi-212 contains both an alpha-emission and a high energy beta providing both localized energy deposition coupled with larger area of homogeneous beta-radiation, treating a wide range of tumor sizes.

References:

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. *CA Cancer J Clin* 2003;53:5-26.
2. Marghood AA, Slade J, Salopek TG, Kopf AW, Bart RS, and Rigel DS. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. *Cancer* 1995;75:707-714.
3. Anderson CM and Buzaid AC. Systematic treatments for advanced cutaneous melanoma. *Oncology* 1995;9:1149-1158.
4. Mastrangelo MJ and Harris DT. Cutaneous melanoma. In: *Current therapy in oncology* (Niederhuber, JE ed.), 1993; pp. 132-138. Decker imprint of Mosby – Yearbook, Inc, St. Louis.
5. Cohen GL, Falkson CI. Current treatment options for malignant melanoma. *Drugs* 1998;55:791-799.
6. Mastrangelo MJ, Bellet RE, Kane MJ, et al. Chemotherapy of melanoma. In: *The chemotherapy source book* (Perry, MC. ed.), 1992; pp. 886-907. William and Wilkins, Baltimore.

II. Publications from DOE DE FG02 95ER61661 funding period:

Chen, J. Q., Cheng, Z., Hoffman, T.J., Jurisson, S.S., and Quinn, T.P. 2000. "Melanoma-Targeting Properties of ^{99m}Tc -Labeled Cyclic α -Melanocyte Stimulating Hormone Peptide Analogues." *Cancer Research* 60, 5649-5658.

Hoffman, T.J., Quinn, T.P., and Volkert, W.A. (2001) "Radiometallated receptor-avid peptide conjugates for specific in vivo targeting of cancer cells." *Nucl. Med. Biol.* 28, 537-539.

Chen, J-Q., Cheng, Z., Owen, N.K., Hoffman, T.J., Miao, Y., Jurisson, S.S., and Quinn, T.P. (2001) "Evaluation of an ^{111}In -DOTA-Rhenium Cyclized α -MSH Analog: A Novel Cyclic-Peptide Analog with Improved Tumor Targeting Properties." *J. Nucl. Med.* 42, 1847-1855.

Chen, J. Q., Cheng, Z., Miao, Y., Jurisson, S.S., and Quinn, T.P. (2002) " ^{99m}Tc - and ^{111}In -labeled α -MSH Peptide Analogs for Malignant Melanoma Targeting." *Cancer* 94, 1196-1201.

Cheng, Z., Chen, J., Owen, N., Miao, Y., Quinn, T.P., and Jurisson, S.S. (2002) "Modification of the structure of a metalloprotein: Synthesis and biological evaluation of ^{111}In labeled DOTA conjugated rhenium cyclized α -MSH analogs. *J. Med. Chem.* 45, 3048-3056.

Miao, Y., Owen, N.K., Whitener, D., Gallazzi, F., Hoffman, T.J. and Quinn, T.P. (2002) "In Vivo Evaluation of ^{188}Re Labeled Alpha-Melanocyte Stimulating Hormone Peptide Analogs for Melanoma Therapy." *Int. J. Cancer* 101, 480-487.

Miao, Y., Owen, N.K., and Quinn, T.P. (2002). "Therapeutic efficacy of ^{188}Re labeled (Arg¹¹)CCMSH peptide in a murine melanoma bearing mouse model." In: *Technetium, Rhenium and other metals in Chemistry and Nuclear Medicine-6*, Eds Nicolini and Mazzi, Servizi Grafici Editoriali, Padova, Italy; pp 375-380.

Miao, Y., Owen, N.K., Whitener, D., Gallazzi, F., Hoffman, T.J. and Quinn, T.P. (2002) "Optimizing the tumor to kidney uptake ratios of ^{188}Re labeled α -MSH peptide analogs through chemical modification." In: *Technetium, Rhenium and other metals in Chemistry and Nuclear Medicine-6*, Eds Nicolini and Mazzi, Servizi Grafici Editoriali, Padova, Italy; pp 567-570.

Miao, Y., Whitener, D., Feng, Weiwei, Owen, N.K., Chen, J-Q., and Quinn, T.P. (2003) Evaluation of the human melanoma targeting properties of radiolabeled α -melanocyte stimulating hormone peptide analogues. *Bioconjugate Chem.* 14, 1177-1184.

Cheng, Z., Chen, J., Quinn, T.P., Jurisson, S.S. (2004) Radioiodination of Rhenium Cyclized alpha-Melanocyte-Stimulating Hormone Resulting in Enhanced Radioactivity Localization and Retention in Melanoma. *Canc. Res* 64, 1411-1418.

Miao, Y., Owen, N.K., Darrell, R., Fisher, D.R., Hoffman, T.J. and Quinn, T.P. (2005) Therapeutic Efficacy of a ^{188}Re Labeled α -Melanocyte Stimulating Hormone Peptide Analogue in Murine and Human Melanoma-bearing Mouse Models." *J. Nucl. Med.* 46, 121-129.

Yubin Miao, Timothy J. Hoffman, Thomas P. Quinn. Tumor targeting properties of ^{90}Y and ^{177}Lu labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model. *Nuclear Medicine and Biology* 2005; 32: 485-493.

Miao, Y., Hylarides, M., Fisher, D.R., Shelton, T., Moore, H., Wester, D.W., Fritzberg, A.R., Winkelmann, C.T., Hoffman, T.J. and Quinn, T.P. (2005) Melanoma Therapy via Peptide-Targeted Alpha-Radiation. *Clinical Cancer Res.* 11, 5616-5621.

Patents issued:

Melanoma Analogs for Potential Radiopharmaceuticals for the Diagnosis and Treatment of Melanoma. United States Patent US 6,338,834

Melanoma Analogs for Potential Radiopharmaceuticals for the Diagnosis and Treatment of Melanoma. United States Patent US 6,607,709

Melanoma Analogs for Potential Radiopharmaceuticals for the Diagnosis and Treatment of Melanoma. United States Patent US 6,680,045